Daiwa Securities Group’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$927K Buy
3,184
+2,033
+177% +$673K ﹤0.01% 845
2026
Q2
$385K Buy
1,151
+205
+22% +$64.9K ﹤0.01% 1009
2026
Q1
$305K Buy
946
+874
+1,214% +$270K ﹤0.01% 983
2025
Q4
$21K Buy
72
+10
+16% +$1.86K ﹤0.01% 1158
2025
Q3
$3K Hold
62
– – ﹤0.01% 1246
2025
Q2
$3K Hold
62
– – ﹤0.01% 1196
2025
Q1
$2K Hold
62
– – ﹤0.01% 1189
2024
Q4
$5K Buy
+62
New +$4.49K ﹤0.01% 1166
2022
Q4
– Sell
-9
Closed – – 1366
2022
Q3
$0 Hold
9
– – ﹤0.01% 1377
2022
Q2
$0 Hold
9
– – ﹤0.01% 1410
2022
Q1
$1K Hold
9
– – ﹤0.01% 1329
2021
Q4
$3K Buy
+9
New +$2.64K ﹤0.01% 1254

Other funds holding PRAX

Daiwa Securities Group's PRAX Position: Q3 2026 in Review

Daiwa Securities Group increased its Praxis Precision Medicines (PRAX) stake by 177% in Q3 2026, buying an estimated $673K and bringing the position to 3,184 shares worth $927K. The position accounts for ﹤0.01% of the portfolio, ranked #845.

Daiwa Securities Group first reported a position in PRAX in Q4 2021 and has held it in 12 quarters since. 339 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • Daiwa Securities Group held 3,184 shares of Praxis Precision Medicines worth $927K as of Q3 2026.
  • Daiwa Securities Group bought 2,033 Praxis Precision Medicines shares in Q3 2026, an estimated $673K.
  • Praxis Precision Medicines made up ﹤0.01% of Daiwa Securities Group's portfolio in Q3 2026, its #845 holding.
  • Daiwa Securities Group first reported a position in Praxis Precision Medicines in Q4 2021 and has held it in 12 quarters since.
  • 339 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Daiwa Securities Group's 13F filing for Q3 2026, filed 29 Oct 2026.